Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avenciguat in Non-Diabetic CKD
NCT04736628Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 2 trial of avenciguat in chronic kidney disease (CKD), sponsored by Boehringer Ingelheim. Started Apr 2021; status: completed.
02
Drugs
avenciguat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04736628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736628.